Publications

Preclinical

Categories
Search
Preclinical
October 2, 2023
World Bispecific Summit
Engineering Trispecific T-cell Engagers to Address Biological Challenges in the Treatment of Solid Tumors
Nina Weisser
Preclinical
June 12, 2023
Journal of Medicinal Chemistry
Structure–Activity Relationships of Bis-Intercalating Peptides and Their Application as Antibody–Drug Conjugate Payloads
Petersen et al.
Preclinical
June 2, 2023
Bioorganic & Medicinal Chemistry Letters
Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates
Brant et al.
Preclinical
May 15, 2023 - May 19, 2023
PEGS
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
Bhojane et al.
Preclinical
May 15, 2023 - May 19, 2023
PEGS
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Garnett et al.
Preclinical
May 10, 2023
STING & TLR-Targeting Therapies Summit
Evaluation of TLR7-agonists as payloads for immune-stimulating antibody conjugates
Graham Garnett
Preclinical
April 18, 2023
AACR
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
Newhook et al.
Preclinical
April 17, 2023
AACR
ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Hernández et al.
Preclinical
April 17, 2023
AACR
Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery
Colombo et al.
Preclinical
April 17, 2023
AACR
ZW270, A Conditionally Masked IL-12 Cytokine Fusion Protein Displaying Potent Anti-tumour Activity Absent of Systemic Toxicity
Escalante et al.
Preclinical
April 17, 2023
AACR
TriTCE CPI, Next Generation Trispecific T Cell Engagers with Integrated Checkpoint Inhibition (CPI) for the Treatment of Solid Tumors
Poffenberger et al.
Preclinical
April 17, 2023
AACR
ZW251, a novel Glypican 3-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Madera et al.